Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 6/20 | 0.48 |
| ▸ | PDE1B | Q01064 | 5/20 | 0.41 |
| ▸ | PDE1A | P54750 | 4/20 | 0.41 |
| ▸ | PDE1C | Q14123 | 4/20 | 0.41 |
| ▸ | PDE2A | O00408 | 3/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15943437 | 0.88 | PDE1B (0.39) | USP1PDE1BPDE1APDE1CPDE2A | |
| SCHEMBL3010414 | 0.79 | PDE1B (0.65) | USP1PDE1BPDE1APDE1CPDE2A | |
| SCHEMBL679995 | 0.78 | PDE1B (0.45) | USP1PDE1BPDE1APDE1CPDE2A | |
| SCHEMBL679944 | 0.77 | PDE1B (0.47) | USP1PDE1BPDE1APDE1CPDE2A | |
| SCHEMBL678876 | 0.77 | PDE1A (0.48) | PDE1BPDE1APDE1CPDE2ALMNA | |
| SCHEMBL15943410 | 0.76 | PDE1B (0.47) | PDE1BPDE1APDE1CPDE2APDE4D | |
| SCHEMBL675773 | 0.76 | USP1 (0.42) | USP1PDE1BPDE2APDE4DDPP4 | |
| SCHEMBL679958 | 0.75 | PDE1B (0.46) | PDE1BPDE1APDE1CPDE2APDE4D | |
| SCHEMBL9608312 | 0.73 | USP1 (0.45) | USP1PDE1BPDE1APDE1CPDE2A | |
| SCHEMBL2612342 | 0.73 | PDE1B (0.55) | USP1PDE1BPDE1APDE1CPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487527-B2 | Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase I | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20150119370-A1 | Organic Compounds | LI PENG (US) | 2015-04-30 | — | — | US | disclosed |
| US-8859564-B2 | Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase 1 | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20110281832-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281832-A1 | ORGANIC COMPOUNDS | CYP2C9, CYP2C19, CYP3A4 | USP1 4645/4885PDE1B 4855/4885PDE1A 4874/4885 |
| US-20150119370-A1 | Organic Compounds | CYP2C19, CYP2C9, CYP3A43 | USP1 3856/4885PDE1B 4882/4885PDE1A 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.